Company:  GALENA BIOPHARMA, INC. (GALE)
Form Type:  8-K
Filing Date:  11/18/2011 
CIK:  0001390478 
Address:  4640 SW MACADAM AVENUE
SUITE 270
 
City, State, Zip:  PORTLAND, Oregon 97239 
Telephone:  855 855 GALE 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.45  
Change: 
-0.02 (-4.26%)  
Trade Time: 
Jul 22  
Market Cap: 
$94.43M
Trade GALE now with 

© 2016  
Description of Business
Galena Biopharma, Inc. ("we," "us," "our," "Galena" or the "Company") is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena's development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company's pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax(TM) (nelipepimut-S), GALE-301 and GALE-302. NeuVax is currently in a pivotal, Phase 3 breast cancer clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b clinical trial given sequentially with GALE-302.
Register and access this filing in:     
  FORM 8-K
    SECTION 3 SECURITIES AND TRADING MARKETS
      Item 3.01 Notice of Delisting or Failure to Satisfy a ...
    SIGNATURES